

Contents

WHO Expert Committee on Specifications for Pharmaceutical Preparations	vi
Declarations of interest	xii
1. Introduction	1
2. General policy	3
2.1 Cross-cutting pharmaceutical quality assurance issues	3
2.2 International collaboration	4
3. Quality control – specifications and tests	7
3.1 <i>The International Pharmacopoeia</i>	7
3.1.1 Updates	7
3.1.2 Workplan 2015–2016	7
3.2 Specifications for medicines, including children’s medicines and radiopharmaceuticals	10
3.2.1 Maternal, newborn, child and adolescent health medicines	10
3.2.2 Antimalarial medicines	11
3.2.3 Antituberculosis medicines	12
3.2.4 Medicines for tropical diseases	12
3.2.5 Medicines for chronic diseases and for mental health	12
3.2.6 Other anti-infective medicines	13
3.2.7 Other medicines	13
3.2.8 Radiopharmaceuticals	14
3.3 General policy	15
4. Quality control – international reference materials (International Chemical Reference Substances and Infrared Reference Spectra)	19
4.1 Update on International Chemical Reference Substances (ICRS), including report of the ICRS Board	19
4.2 General policy	20
4.2.1 Chapter on reference substances and reference spectra	20
5. Quality control – national laboratories	21
5.1 External quality assurance assessment scheme	21
5.2 Guidance on testing of “suspect” substandard/spurious/false-labelled/falsified/counterfeit medicines	21
6. Prequalification of quality control laboratories	22
6.1 Update on the prequalification of quality control laboratories	22
6.2 Update on WHO quality monitoring projects	22
7. Quality assurance – collaboration initiatives	23
7.1 International meetings of world pharmacopoeias	23
7.2 Good pharmacopoeial practices	23
7.3 FIP–WHO technical guidelines: points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products	24

8. Quality assurance – good manufacturing practices	26
8.1 Update of WHO good manufacturing practices for biologicals	26
8.2 Update of questions and answers for WHO good manufacturing practices for active pharmaceutical ingredients	26
8.3 Update of WHO good manufacturing practices: validation	27
8.4 Update of model inspection report	27
8.5 Update and recommendations from the inspectors' meeting	28
8.5.1 Supplementary guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms	28
8.5.2 Risk classification of inspection observations	28
8.6 Guidance on good data and record management practices	29
9. Quality assurance – distribution and trade of pharmaceuticals	30
9.1 Good trade and distribution practices for starting materials	30
9.2 WHO Certification scheme on the quality of pharmaceutical products moving in international commerce – questions and answers	30
9.3 Guidance on medicines quality surveys	31
9.4 Update on the monitoring and surveillance project	32
10. Prequalification of priority essential medicines and active pharmaceutical ingredients	33
10.1 Update on the Prequalification Team managed by WHO	33
10.2 Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines	34
11. Regulatory guidance	35
11.1 Guidance for organizations performing in vivo bioequivalence studies	35
11.2 WHO general guidance on variations to multisource pharmaceutical products	35
11.3 Update of biowaiver principles for assessment of interchangeable multisource (generic) products	36
11.4 Update of biowaiver list based on the WHO Model List of Essential Medicines	37
11.5 Update of international comparator products list for equivalence assessment of interchangeable multisource (generic) products	37
11.6 Good regulatory practices	38
12. Nomenclature, terminology and databases	40
13. Summary and recommendations	42
Acknowledgements	48
Annex 1	
Good pharmacopoeial practices	67
Annex 2	
FIP–WHO technical guidelines: Points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products	87

Annex 3		
	WHO good manufacturing practices for biological products	111
Annex 4		
	Guidance on good manufacturing practices: inspection report	149
Annex 5		
	Guidance on good data and record management practices	165
Annex 6		
	Good trade and distribution practices for pharmaceutical starting materials	211
Annex 7		
	Guidelines on the conduct of surveys of the quality of medicines	227
Annex 8		
	Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines	263
Annex 9		
	Guidance for organizations performing in vivo bioequivalence studies	305
Annex 10		
	WHO general guidance on variations to multisource pharmaceutical products	347